- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 8 - A Managed Care Approach to Immunotherapy
As the panelists discuss the skepticism often associated with treatment outcomes of immunotherapy when compared with outcomes of standard treatment options such as chemotherapy, the panelists conclude that tumor response (or reduction) should not be considered an ultimate end point when determining results.
In practice, Daniel J. George, MD, believes that patients’ goals are achieved when they can experience a decent quality of life without experiencing any disease progression. Dr George further explains that some patients that have tumor burden still experience a fantastic quality of life if their treatment side effects are managed correctly.
Jeffrey Weber, MD, PhD, agrees with Dr George and explains that although tumor response is a desirable end point, as recognized by the FDA, it should be perceived as a useful, but not ultimate, result factor.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Specialty Drug Users to Gain Relief Under Medicare Reforms
May 16th 2025A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often represent a significant cost burden for Medicare Part D beneficiaries and which were selected for 2026 drug price negotiation under the Inflation Reduction Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Navigation and Clinician Payment Investments Enhance Colorectal Cancer Screening Benefits
May 15th 2025Investing in patient navigation and clinician incentives ensures colorectal cancer screening completion, improves early detection, reduces disparities, achieves cost savings, and advances population health for all stakeholders.
Read More
